Taburnaemine F






Names

    • Taburnaemine F

Attributes

  • Canonical SMILES

    OC[C@@]1(C(OC)=O)[C@@](CC2=C([C@@H](C3=C4C(C([C@@H]5CN([C@@H]6O5)C7[C@@]8(C(OC)=O)C[C@@]6([H])C[C@]7([H])CC)=C8N4)=CC=C3OC)C[C@]/91[H])NC%10=C2C=CC=C%10)([H])N(C)CC9=C\C

  • InChI

    InChI=1S/C44H52N4O7/c1-7-22-15-24-18-43(41(50)53-5)38-35(32-20-48(39(22)43)40(24)55-32)26-13-14-31(52-4)34(37(26)46-38)28-16-29-23(8-2)19-47(3)33(44(29,21-49)42(51)54-6)17-27-25-11-9-10-12-30(25)45-36(27)28/h8-14,22,24,28-29,32-33,39-40,45-46,49H,7,15-21H2,1-6H3/b23-8-/t22-,24+,28+,29+,32-,33-,39?,40+,43+,44-/m0/s1

  • Molecule Class: Alkaloids
  • TPSA: 129.35000000000002
  • #RotBonds: 6
  • MW: 748.9209999999999
  • HBD: 3
  • HBA: 9
  • logP: 5.706300000000005
  • Chemical Formula: C44H52N4O7


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. corymbosa Malaysia, China 1679252 GK604

External Databases


References

  • Taburnaemines A-I, Cytotoxic Vobasinyl-Iboga-Type Bisindole Alkaloids from Tabernaemontana corymbosa. J Nat Prod, 2018 (PMID 29319316).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Antiproliferative

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -6.0
    Human Oral Bioavailability 20% Non-Bioavailable
    Human Intestinal Absorption Non-Absorbed
    Madin-Darby Canine Kidney 119.68
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Non-Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability 16421.24
    Distribution Blood-Brain Barrier (Central Nervous System) -3.46
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 1.11
    Plasma Protein Binding 83.93
    Steady State Volume of Distribution 4.5
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Inhibitor
    CYP 1A2 substrate Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Non-Substrate
    CYP 3A4 Inhibitor Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Inhibitor
    Excretion Clearance 9.65
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Toxic
    Bee Toxic
    Bioconcentration Factor -384.85
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -1.4
    Liver Injury II Toxic
    hERG Blockers Toxic
    Daphnia Maga 5.18
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Toxic
    T. Pyriformis -29800479.38
    Rat (Acute) 2.85
    Rat (Chronic Oral) 2.57
    Fathead Minnow 37618.8
    Respiratory Disease Toxic
    Skin Sensitisation Safe
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 3347778.68
    Hydration Free Energy -2.92
    Log(D) at pH=7.4 5.17
    Log(P) 5.18
    Log S -5.53
    Log(Vapor Pressure) -110164.39
    Melting Point 278.55
    pKa Acid -753.01
    pKa Basic 6.36